当前位置：
X-MOL 学术
›
J. Hematol. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
Journal of Hematology & Oncology ( IF 28.5 ) Pub Date : 2021-06-21 , DOI: 10.1186/s13045-021-01095-1 Jian Li 1 , Yanhong Deng 2 , Weijie Zhang 3 , Ai-Ping Zhou 4 , Weijian Guo 5, 6 , Jianwei Yang 7 , Ying Yuan 8 , Liangjun Zhu 9 , Shukui Qin 10 , Silong Xiang 11 , Haolan Lu 11 , John Gong 11 , Ting Xu 12 , David Liu 11 , Lin Shen 1
Journal of Hematology & Oncology ( IF 28.5 ) Pub Date : 2021-06-21 , DOI: 10.1186/s13045-021-01095-1 Jian Li 1 , Yanhong Deng 2 , Weijie Zhang 3 , Ai-Ping Zhou 4 , Weijian Guo 5, 6 , Jianwei Yang 7 , Ying Yuan 8 , Liangjun Zhu 9 , Shukui Qin 10 , Silong Xiang 11 , Haolan Lu 11 , John Gong 11 , Ting Xu 12 , David Liu 11 , Lin Shen 1
Affiliation
Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused to an Fc fragment, represents a potential advance because it can be conveniently administered subcutaneously. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of envafolimab in patients with previously treated advanced dMMR/MSI-H tumors from 25 clinical sites across China. Adults with histologically confirmed locally advanced or metastatic malignant dMMR/MSI-H solid tumors received weekly 150 mg subcutaneous envafolimab injections in a 28-day treatment cycle. The primary efficacy endpoint was the objective response rate (assessed by a blinded independent review committee). Secondary efficacy outcomes were disease control rate, duration of response, progression-free survival, and overall survival. One hundred and three patients (65 with colorectal cancer, 18 with gastric cancer, and 20 with other solid tumors) were enrolled. Median follow-up was 11.5 months. The objective response rate was 42.7% (95% confidence interval [CI] 33.0–52.8), and the disease control rate was 66.0% (95% CI 56.0–75.1). Median duration of response was not reached; the duration of response rate at 12 months was 92.2% (95% CI 77.5–97.4). Median progression-free survival was 11.1 months (95% CI 5.5 to not evaluable). Overall survival at 12 months was 74.6% (95% CI 64.7–82.1). Sixteen patients (16%) had at least one grade 3 or 4 related treatment-emergent adverse event. No grade 5 treatment-emergent adverse events related to envafolimab were reported. Injection site reactions, all grade 1–2, were reported in nine patients (9%), but there were no infusion reactions. Eight patients (8%) had grade 3 or 4 immune-related adverse events. This is the first pivotal phase 2 study to examine the efficacy and safety of a single-domain immune checkpoint antibody in the treatment of cancer. Envafolimab was effective and had acceptable safety in the treatment of previously treated advanced dMMR/MSI-H solid tumors. As the first single-domain PD-L1-targeting antibody administered by rapid subcutaneous injection, envafolimab has the potential to be a significant advance in the treatment of cancer. Trial registration ClinicalTrials.gov, NCT03667170. Registered 10 September 2018—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03667170 .
更新日期：2021-06-21
京公网安备 11010802027423号